Literature DB >> 15066961

Hypertrophy of the heart: a new therapeutic target?

Norbert Frey1, Hugo A Katus, Eric N Olson, Joseph A Hill.   

Abstract

Recent studies call into question the necessity of hypertrophic growth of the heart as a "compensatory" response to hemodynamic stress. These findings, coupled with recent progress in dissecting the molecular bases of hypertrophy, raise the prospect of suppressing hypertrophy without provoking circulatory insufficiency. In this article, we focus on signaling pathways that hold promise as potential targets for therapeutic intervention. We also summarize observations from animal models and clinical trials that suggest benefit from an antihypertrophic strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066961     DOI: 10.1161/01.CIR.0000120390.68287.BB

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  288 in total

1.  The direct incorporation of perfusion defect information to define ischemia and infarction in a finite element model of the left ventricle.

Authors:  Alexander I Veress; George S K Fung; Taek-Soo Lee; Benjamin M W Tsui; Gregory A Kicska; W Paul Segars; Grant T Gullberg
Journal:  J Biomech Eng       Date:  2015-02-25       Impact factor: 2.097

2.  O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.

Authors:  Heberty T Facundo; Robert E Brainard; Lewis J Watson; Gladys A Ngoh; Tariq Hamid; Sumanth D Prabhu; Steven P Jones
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-09       Impact factor: 4.733

Review 3.  Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes.

Authors:  Robert B Hamanaka; Navdeep S Chandel
Journal:  Trends Biochem Sci       Date:  2010-04-27       Impact factor: 13.807

4.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

Review 5.  microRNAs in cardiovascular development.

Authors:  Jinghai Chen; Da-Zhi Wang
Journal:  J Mol Cell Cardiol       Date:  2012-01-24       Impact factor: 5.000

6.  PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.

Authors:  Qian Li; Zhuo-Ming Li; Shu-Ya Sun; Lu-Ping Wang; Pan-Xia Wang; Zhen Guo; Han-Wei Yang; Jian-Tao Ye; Jing Lu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-07-20       Impact factor: 6.150

7.  Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice.

Authors:  Yi Liu; Xiao-Li Jiang; Yu Liu; Ding-Sheng Jiang; Yan Zhang; Rui Zhang; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Cardiovasc Res       Date:  2013-11-26       Impact factor: 10.787

8.  Mitochondrial fission is required for cardiomyocyte hypertrophy mediated by a Ca2+-calcineurin signaling pathway.

Authors:  Christian Pennanen; Valentina Parra; Camila López-Crisosto; Pablo E Morales; Andrea Del Campo; Tomás Gutierrez; Pablo Rivera-Mejías; Jovan Kuzmicic; Mario Chiong; Antonio Zorzano; Beverly A Rothermel; Sergio Lavandero
Journal:  J Cell Sci       Date:  2014-04-28       Impact factor: 5.285

9.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.

Authors:  Hui-Hua Li; Vishram Kedar; Chunlian Zhang; Holly McDonough; Ranjana Arya; Da-Zhi Wang; Cam Patterson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy.

Authors:  Cosmo Damiano del Vescovo; Susanna Cotecchia; Dario Diviani
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.